Brief: Compass Therapeutics - Ended 2023 With Estimated $152 Million In Cash, Marketable Securities

Compass Therapeutics

05/01/2024 13:56

Jan 5 (Reuters) - Compass Therapeutics Inc.  CMPX.O :
    * ENDED 2023 WITH ESTIMATED $152 MILLION IN CASH, MARKETABLE
SECURITIES,WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO
MID-YEAR 2026
    * FOLLOWING FDA ACCEPTANCE OF THE CTX-8371 IND IN LATE 2023,
WE
EXPECT TO DOSE THE FIRST PATIENT IN 1Q 2024.
    * ENROLLMENT OF PATIENTS IN COMPANION-003,PHASE 2 STUDY OF
CTX-009
IN PATIENTS WITH ADVANCED COLORECTAL CANCER,EXTENDED INTO Q1 OF
2024

Source text for Eikon:  ID: 
Further company coverage:  CMPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))